Suggested remit: To appraise the clinical and cost effectiveness of tislelizumab in combination within its marketing authorisation for untreated advanced non-small-cell lung cancer.
|
Status
|
In progress
|
|
Technology type
|
Medicine
|
|
Decision
|
Selected
|
|
Reason for decision
|
Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
|
|
Further information
|
The company has informed NICE that it will not provide an evidence submission for this appraisal. Therefore, we are suspending the appraisal while we consider the next steps.
|
| Process |
STA Standard
|
| ID number |
6162
|
Project Team
| Project lead |
Emily Richards |
Email enquiries
|
Date
|
Update
|
|
15 January 2025 - 12 February 2025
|
Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6162 |
|
15 January 2025
|
In progress. Scoping commenced |
|
04 June 2024
|
Awaiting development. Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin during mid-April 2025. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission. |
|
04 June 2024
|
Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin during mid-April 2025. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission. |
|
16 January 2024
|
For information, tislelizumab has now been acquired by the company Beigene. NICE are liaising with the company regarding appropriate timelines for this appraisal and further information will be available in due course. |
|
09 August 2022
|
Suspended. The company has informed NICE that it will not provide an evidence submission for this appraisal. Therefore, we are suspending the appraisal while we consider the next steps. |
For further information on our processes and methods, please see our CHTE processes and methods manual